New nerve pain drug shows promise in Year-Long trial
NCT ID NCT05890053
First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study tested the long-term safety and effectiveness of HSK16149, a drug for nerve pain, in 301 Chinese patients over 52 weeks. All participants had previously completed a shorter trial and tolerated the drug. Researchers tracked side effects and pain scores to see if the drug remains safe and helpful over time.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HSK16149
What this could lead to
If successful, this could provide a long-term treatment option for people with nerve pain.
What could go wrong
This is an extension study, so participants already tolerated the drug. However, long-term side effects are still being monitored, and results may not apply to non-Chinese populations.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PERIPHERAL NEUROPATHIC PAIN are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Baotou Central Hospital
Baotou, Neimenggu, China
-
Beijing Pinggu District Hospital
Beijing, Beijing Municipality, China
-
Cangzhou People's Hospital
Cangzhou, Hebei, China
-
Emergency General Hospital
Beijing, Beijing Municipality, China
-
Jinan Central Hospital
Jinan, Shandong, China
-
Kaifeng Hospital of Traditional Chinese Medicine
Kaifeng, Henan, China
-
Nanjing First People's Hospital
Nanjing, Jiangsu, China
-
Nanyang First People's Hospital
Nanyang, Henan, China
-
Peking University First Hospital
Beijing, Beijing Municipality, 100034, China
-
Pingxiang People's Hospital
Pingxiang, Jiangxi, China
-
Taizhou First People's Hospital
Taizhou, Zhejiang, China
-
The First Affiliated Hospital of Anhui Medical University
Hefei, Anhui, China
-
The First Affiliated Hospital of Henan University of Science and Technology
Luoyang, Henan, China
-
The First Affiliated Hospital of Xi'an Medical University
Xi’an, Shanxi, China
-
The First Hospital of Jilin University
Changchun, Jilin, China
-
The First Hospital of Lanzhou University
Lanzhou, Gansu, China
-
The Second Affiliated Hospital of Anhui Medical University
Hefei, Anhui, China
-
The Second People's Hospital of Yibin
Yibin, Sichuan, China
-
The Third Hospital of Hebei Medical University
Shijiangzhuang, Hebei, China
-
The Three Gorges Hospital Affiliated to Chongqing Medical University
Chongqing, Chongqing Municipality, China
-
Wuhan Central Hospital
Wuhan, Hubei, China
-
Yuncheng Central Hospital
Yuncheng, Shanxi, China
-
Zhejiang Provincial People's Hospital
Hangzhou, Zhejiang, China
-
Zhujiang Hospital of Southern Medical University
Guangzhou, Guangdong, China